Company Overview of Polyphor Ltd
Polyphor Ltd. is a pharmaceutical company that focuses on the discovery and development of macrocycle drugs addressing unmet medical needs. Its products include POL6326, an antagonist of the chemokine receptor CXCR4 for stem cell transplantation, tissue repair, and combination treatments in oncology; POL7080, a pseudomonas specific antibiotic with a mode of action to treat pseudomonas infections; and POL6014, an inhaled inhibitor of human neutrophil elastase for the treatment of Alpha-1 antitrypsin deficiency, cystic fibrosis, and other lung diseases. The company also develops solutions for multiple myeloma. Its pipeline of macrocycles also targets leukemia and chronic obstructive pulmonary ...
Founded in 1996
Key Executives for Polyphor Ltd
Co-Founder and Chief Scientific Officer
Head of Technology Platforms
Head of the Internal Services
Compensation as of Fiscal Year 2014.
Polyphor Ltd Key Developments
Polyphor Ltd. Announces Management Changes
Mar 17 15
Polyphor Ltd. announced the appointment of Michael Altorfer as new CEO and successor of Jean-Pierre Obrecht as of March 31, 2015. Jean-Pierre Obrecht will continue to support the company in his role as a Member of the Board of Directors. Michael Altorfer joined Polyphor in 2001. He has served Polyphor in various functions, first as Head of the Small Molecule Service Business, then as Chief Financial Officer and Head of Corporate Development, and was Chief Operating Officer since 2014. The company also announced that it recently appointed Leon Hooftman, M.D., as Chief Medical Officer and Adesh Kaul as Head Corporate Development to complement Polyphor's executive management team. Adesh Kaul has extensive experience in the area of corporate-and business development in the Pharma and Biotech industry. Since 2009 he worked at Basilea Pharmaceutica AG, from 2010 as Head Business Development & Investor Relations, from 2009 to 2010 as Head Public Relations & Corporate Communications. Leon Hooftman is an accomplished pharmaceutical physician with more than 20 years of experience in pharmaceutical drug development in the areas of immunology, haematology and oncology, and has several New Drug Applications to his credit. Before joining Polyphor Dr. Hooftman was CMO of Synthon BV.
Polyphor Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015
Jan 29 15
Polyphor Ltd Presents at BIO-Europe Spring 2015, Mar-09-2015 . Venue: Paris Expo - Porte de Versailles, Hall 5, Paris, France.
Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM
Mar 19 14
Polyphor Ltd Presents at UBS Global Healthcare Conference, May-21-2014 12:00 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Jean-Pierre Obrecht, Co-Founder, Chief Executive Officer and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|